TerminatedPhase 2NCT00003910
Methotrexate With or Without Cyclophosphamide in Treating Patients With Lymphocytic Leukemia
Studying Aggressive NK-cell leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Eastern Cooperative Oncology Group
- Principal Investigator
- Thomas P. Loughran, MDMilton S. Hershey Medical Center
- Intervention
- Cyclophosphamide(drug)
- Enrollment
- 59 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 1999 – 2012
Study locations (30)
- Aurora Presbyterian Hospital, Aurora, Colorado, United States
- Boulder Community Hospital, Boulder, Colorado, United States
- Penrose Cancer Center at Penrose Hospital, Colorado Springs, Colorado, United States
- St. Anthony Central Hospital, Denver, Colorado, United States
- Porter Adventist Hospital, Denver, Colorado, United States
- Presbyterian - St. Luke's Medical Center, Denver, Colorado, United States
- St. Joseph Hospital, Denver, Colorado, United States
- Rose Medical Center, Denver, Colorado, United States
- CCOP - Colorado Cancer Research Program, Denver, Colorado, United States
- Swedish Medical Center, Englewood, Colorado, United States
- St. Mary's Regional Cancer Center at St. Mary's Hospital and Medical Center, Grand Junction, Colorado, United States
- North Colorado Medical Center, Greeley, Colorado, United States
- Sky Ridge Medical Center, Lone Tree, Colorado, United States
- Hope Cancer Care Center at Longmont United Hospital, Longmont, Colorado, United States
- McKee Medical Center, Loveland, Colorado, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00003910 on ClinicalTrials.govOther trials for Aggressive NK-cell leukemia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT06716658JAK1 Inhibitor Golidocitnib for the Treatment of Relapsed/Refractory Indolent T/NK-cell LymphomasInstitute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE1, PHASE2NCT05863234Safety Evaluation Study for Patients With Aggressive NK-cell LeukemiaHiroshima University Hospital
- RECRUITINGPHASE2NCT05941156Clinical Study of Anti-CD56-CAR-T in the Treatment of Relapsed/Refractory NK/T Cell Lymphoma /NK Cell LeukemiaThe Affiliated Hospital of Xuzhou Medical University